AzurRx BioPharma Reports Positive Interim P-II Data of MS1819 + PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
Shots: The interim data from 18 patients out of 20 in P-II trial evaluating the safety, tolerability, and efficacy of MS1819 (700/1200/2240 mg, qd, for 15 days/dosing level) + PERT aged 12 yrs or older in CF patients for EPI The 1EP & 2EP of the trial demonstrated improvement in CFA, improvement in stool weight, […]